1,160 research outputs found
Tracing jet emission at the base of a high-mass YSO. First AMBER/VLTI observations of the Brγemission in IRAS 13481-6124
This is the author accepted manuscript. The final version is available from the publisher via the DOI in this record.To probe the circumstellar environment of IRAS 13481-6124, a 20 M_sun high-mass young stellar object (HMYSO) with a parsec-scale jet and accretion disc, we investigate the origin of its Br\gamma-emission line through NIR interferometry. We present the first AMBER/VLTI observations of the Br\gamma-emitting region in an HMYSO at R~1500. Our AMBER/VLTI observations reveal a spatially and spectrally resolved Br\gamma-line in emission with a strong P Cygni profile, indicating outflowing matter with a terminal velocity of ~500 km/s. Visibilities, differential phases, and closure phases are detected in our observations within the spectral line and in the adjacent continuum. Both total visibilities (continuum plus line emitting region) and pure-line visibilities indicate that the Br\gamma-emitting region is more compact (2-4 mas in diameter or ~6-13 au at 3.2 kpc) than the continuum-emitting region (~5.4 mas or ~17 au). The absorption feature is also spatially resolved at the longest baselines (81 and 85 m) and has a visibility that is slightly smaller than the continuum-emitting region. The differential phases at the four longest baselines display an \u2018S\u2019-shaped structure across the line, peaking in the blue- and red-shifted high-velocity components. The calibrated photocentre shifts are aligned with the known jet axis, i.e they are probably tracing an ionised jet. The high-velocity components (v_r~100-500 km/s) are located far from the source, whereas the low-velocity components (0-100 km/s) are observed to be closer, indicating a strong acceleration of the gas flow in the inner 10 au. Finally, a non-zero closure phase along the continuum is detected. By comparing our observations with the synthetic images of the continuum around 2.16 um, we confirm that this feature originates from the asymmetric brightness distribution of the continuum owing to the inclination of the inner disc.A.C.G., R.G.L., and T.P.R. were supported by Science
Foundation Ireland, grant 13/ERC/I2907. A.K. and S.K. acknowledge support
from a STFC Ernest Rutherford fellowship and grant (ST/J004030/1,
ST/K003445/1), and Marie-Sklodowska Curie CIG grant (Ref. 618910). A.S.
was supported by the Deutsche Forschungsgemeinschaft (DFG) Priority Program
1573. This research has also made use of NASA’s Astrophysics Data System
Bibliographic Services and the SIMBAD database operated at the CDS,
Strasbourg, France
Cortical thickness, surface area and volume measures in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy
OBJECTIVE
Parkinson's disease (PD), Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) are neurodegenerative diseases that can be difficult to distinguish clinically. The objective of the current study was to use surface-based analysis techniques to assess cortical thickness, surface area and grey matter volume to identify unique morphological patterns of cortical atrophy in PD, MSA and PSP and to relate these patterns of change to disease duration and clinical features.
METHODS
High resolution 3D T1-weighted MRI volumes were acquired from 14 PD patients, 18 MSA, 14 PSP and 19 healthy control participants. Cortical thickness, surface area and volume analyses were carried out using the automated surface-based analysis package FreeSurfer (version 5.1.0). Measures of disease severity and duration were assessed for correlation with cortical morphometric changes in each clinical group.
RESULTS
Results show that in PSP, widespread cortical thinning and volume loss occurs within the frontal lobe, particularly the superior frontal gyrus. In addition, PSP patients also displayed increased surface area in the pericalcarine. In comparison, PD and MSA did not display significant changes in cortical morphology.
CONCLUSION
These results demonstrate that patients with clinically established PSP exhibit distinct patterns of cortical atrophy, particularly affecting the frontal lobe. These results could be used in the future to develop a useful clinical application of MRI to distinguish PSP patients from PD and MSA patients
Measurement of the antineutrino neutral-current elastic differential cross section
arXiv:1309.7257v1 [hep-ex
Association of specific chromosome alterations with tumour phenotype in posterior uveal melanoma
Posterior uveal melanomas have recurrent alterations of chromosomes 1, 3, 6 and 8. In particular, changes of chromosomes 3 and 8 occur in association, appear to characterize those tumours with a ciliary body component, and have been shown to be of prognostic significance. The relevance of other chromosome alterations is less certain. We have performed cytogenetic analysis on 42 previously untreated primary posterior uveal melanomas. Of interest was the observation that as tumour size increased the involvement of specific chromosome changes, and the amount of chromosome abnormalities likewise increased. Loss, or partial deletions, of the short arm of chromosome 1 were found to associate with larger ciliary body melanomas; typically, loss of the short arm resulted from unbalanced translocations, the partners of which varied. Trisomy of chromosome 21 occurred more often in ciliary body melanomas, whilst rearrangements of chromosomes 6 and 11 were primarily related to choroidal melanomas. Our results imply that alterations of chromosome 1 are important in the progression of some uveal melanomas, and that other chromosome abnormalities, besides those of chromosomes 3 and 8, are associated with ocular tumours of particular locations. © 2000 Cancer Research Campaig
Potential Impact of Benzodiazepine Use on the Rate of Hip Fractures in Five Large European Countries and the United States
Benzodiazepine use increases the risk of falls and has been associated with an increased risk of hip fractures. Our aim was to estimate the possible population impact of the use of benzodiazepines on the rate of hip fracture in France, Germany, Italy, Spain, the United Kingdom, and the United States. We conducted a literature review to estimate the pooled relative risk (RR) for hip fractures and use of benzodiazepines. Prevalence rates of benzodiazepine use in 2009 were calculated for each country using the IMS MIDAS database and three public databases in Denmark, the Netherlands, and Norway. Both the RR and prevalence rates were used for calculation of population attributable risks (PARs) of hip fractures associated with benzodiazepine use. The literature review showed an increased risk of hip fractures in benzodiazepine users (RR = 1.4, 95 % CI 1.2–1.6). Rate of benzodiazepine use showed considerable differences between countries, ranging from 4.7 % to 22.3 % of population ever in a 1-year period. These are reflected in results for the PARs; estimated attributions of benzodiazepines to the rate of hip fractures were 1.8 %, 95 % CI 1.1–2.6 (Germany); 2.0 %, 95 % CI 1.2–2.8 (United Kingdom); 5.2 %, 95 % CI 3.2–7.3 (Italy); 7.4 %, 95 % CI 4.5–10.0 (France); 8.0 %, 95 % CI 4.9–11.0 (United States); and 8.2 %, 95 % CI 5.1–12.0 (Spain). PAR estimates suggest that the potential attribution of benzodiazepine use on the population rate of hip fractures in the five specified European countries and the United States varies between 1.8 % and 8.2 %. During the next phase of the IMI-PROTECT study, a comparison with individual patient data will show whether this approach is valid
The ACUTE (Ambulance CPAP: Use, Treatment effect and economics) feasibility study: a pilot randomised controlled trial of prehospital CPAP for acute respiratory failure
Background: Acute respiratory failure (ARF) is a common and life-threatening medical emergency. Standard prehospital
management involves controlled oxygen therapy and disease-specific ancillary treatments. Continuous positive airway
pressure (CPAP) is a potentially beneficial alternative treatment that could be delivered by emergency medical services.
However, it is uncertain whether this treatment could work effectively in United Kingdom National Health Service (NHS)
ambulance services and if it represents value for money.
Methods: An individual patient randomised controlled external pilot trial will be conducted comparing prehospital CPAP
to standard oxygen therapy for ARF. Adults presenting to ambulance service clinicians will be eligible if they have
respiratory distress with peripheral oxygen saturation below British Thoracic Society (BTS) target levels, despite titrated
supplemental oxygen. Enrolled patients will be allocated (1:1 simple randomisation) to prehospital CPAP (O_two system)
or standard oxygen therapy using identical sealed boxes. Feasibility outcomes will include incidence of recruited eligible
patients, number of erroneously recruited patients and proportion of cases adhering to allocation schedule and
treatment, followed up at 30 days and with complete data collection. Effectiveness outcomes will comprise survival at
30 days (definitive trial primary end point), endotracheal intubation, admission to critical care, length of hospital stay,
visual analogue scale (VAS) dyspnoea score, EQ-5D-5L and health care resource use at 30 days. The cost-effectiveness
of CPAP, and of conducting a definitive trial, will be evaluated by updating an existing economic model. The trial aims
to recruit 120 patients over 12 months from four regional ambulance hubs within the West Midlands Ambulance
Service (WMAS). This sample size will allow estimation of feasibility outcomes with a precision of < 5%. Feasibility and
effectiveness outcomes will be reported descriptively for the whole trial population, and each trial arm, together with
their 95% confidence intervals.
Discussion: This study will determine if it is feasible, acceptable and cost-effective to undertake a full-scale trial
comparing CPAP and standard oxygen treatment, delivered by ambulance service clinicians for ARF. This will inform
NHS practice and prevent inappropriate prehospital CPAP adoption on the basis of limited evidence and at a
potentially substantial cost.
Trial registration: ISRCTN12048261. Registered on 30 August 2017. http://www.isrctn.com/ISRCTN1204826
Symptoms and quality of life in late stage Parkinson syndromes: a longitudinal community study of predictive factors
BACKGROUND
Palliative care is increasingly offered earlier in the cancer trajectory but rarely in Idiopathic Parkinson's Disease(IPD), Progressive Supranuclear Palsy(PSP) or Multiple System Atrophy(MSA). There is little longitudinal data of people with late stage disease to understand levels of need. We aimed to determine how symptoms and quality of life of these patients change over time; and what demographic and clinical factors predicted changes.
METHODS
We recruited 82 patients into a longitudinal study, consenting patients with a diagnosis of IPD, MSA or PSP, stages 3-5 Hoehn and Yahr(H&Y). At baseline and then on up to 3 occasions over one year, we collected self-reported demographic, clinical, symptom, palliative and quality of life data, using Parkinson's specific and generic validated scales, including the Palliative care Outcome Scale (POS). We tested for predictors using multivariable analysis, adjusting for confounders.
FINDINGS
Over two thirds of patients had severe disability, over one third being wheelchair-bound/bedridden. Symptoms were highly prevalent in all conditions - mean (SD) of 10.6(4.0) symptoms. More than 50% of the MSA and PSP patients died over the year. Over the year, half of the patients showed either an upward (worsening, 24/60) or fluctuant (8/60) trajectory for POS and symptoms. The strongest predictors of higher levels of symptoms at the end of follow-up were initial scores on POS (AOR 1.30; 95%CI:1.05-1.60) and being male (AOR 5.18; 95% CI 1.17 to 22.92), both were more predictive than initial H&Y scores.
INTERPRETATION
The findings point to profound and complex mix of non-motor and motor symptoms in patients with late stage IPD, MSA and PSP. Symptoms are not resolved and half of the patients deteriorate. Palliative problems are predictive of future symptoms, suggesting that an early palliative assessment might help screen for those in need of earlier intervention
ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients
[Background]
Tumor expression of estrogen receptor (ER) is an important marker of prognosis, and is predictive of response to endocrine therapy in breast cancer. Several studies have observed that epigenetic events, such methylation of cytosines and deacetylation of histones, are involved in the complex mechanisms that regulate promoter transcription. However, the exact interplay of these factors in transcription activity is not well understood. In this study, we explored the relationship between ER expression status in tumor tissue samples and the methylation of the 5′ CpG promoter region of the estrogen receptor gene (ESR1) isolated from free circulating DNA (fcDNA) in plasma samples from breast cancer patients.
[Methods]
Patients (n = 110) with non-metastatic breast cancer had analyses performed of ER expression (luminal phenotype in tumor tissue, by immunohistochemistry method), and the ESR1-DNA methylation status (fcDNA in plasma, by quantitative methylation specific PCR technique).
[Results]
Our results showed a significant association between presence of methylated ESR1 in patients with breast cancer and ER negative status in the tumor tissue (p = 0.0179). There was a trend towards a higher probability of ESR1-methylation in those phenotypes with poor prognosis i.e. 80% of triple negative patients, 60% of HER2 patients, compared to 28% and 5.9% of patients with better prognosis such as luminal A and luminal B, respectively.
[Conclusion]
Silencing, by methylation, of the promoter region of the ESR1 affects the expression of the estrogen receptor protein in tumors of breast cancer patients; high methylation of ESR1-DNA is associated with estrogen receptor negative status which, in turn, may be implicated in the patient’s resistance to hormonal treatment in breast cancer. As such, epigenetic markers in plasma may be of interest as new targets for anticancer therapy, especially with respect to endocrine treatment.The study was funded, in part, by a grant from the Ministerio de Educación y Ciencia (CICYT: SAF 2004–00889)
Psychotropic drugs and the risk of fractures in old age: a prospective population-based study
<p>Abstract</p> <p>Background</p> <p>There is evidence that the use of any psychotropic and the concomitant use of two or more benzodiazepines are related to an increased risk of fractures in old age. However, also controversial results exist. The aim was to describe associations between the use of a psychotropic drug, or the concomitant use of two or more of these drugs and the risk of fractures in a population aged 65 years or over.</p> <p>Methods</p> <p>This study was a part of a prospective longitudinal population-based study carried out in the municipality of Lieto, South-Western Finland. The objective was to describe gender-specific associations between the use of one psychotropic drug [benzodiazepine (BZD), antipsychotic (AP) or antidepressant (AD)] or the concomitant use of two or more psychotropic drugs and the risk of fractures in a population 65 years or over. Subjects were participants in the first wave of the Lieto study in 1990-1991, and they were followed up until the end of 1996. Information about fractures confirmed with radiology reports in 1,177 subjects (482 men and 695 women) during the follow-up was collected from medical records. Two follow-up periods (three and six years) were used, and previously found risk factors of fractures were adjusted as confounding factors separately for men and women. The Poisson regression model was used in the analyses.</p> <p>Results</p> <p>The concomitant use of two or more BZDs and the concomitant use of two or more APs were related to an increased risk of fractures during both follow-up periods after adjusting for confounding factors in men. No similar associations were found in women.</p> <p>Conclusions</p> <p>The concomitant use of several BZDs and that of several APs are associated with an increase in the risk of fractures in older men. Our findings show only risk relations. We cannot draw the conclusion that these drug combinations are causes of fractures.</p
Anti-angiogenic therapies for the treatment of angiosarcoma: a clinical update
Summary: Angiosarcomas are rare aggressive endothelial tumours, and are associated with a poor prognosis. Due to their vascular nature, there is great interest in their response to anti-angiogenic agents. A number of small prospective studies have reported angiosarcoma response to vascular-targeted agents, including agents that target vascular endothelial growth factor. To date, the response to these agents has been disappointing, and similar to the response observed in other soft tissue sarcoma subtypes. This short review will summarise the recent data in this field
- …